Get the Stockscreener App
26.56
1.37%
-0.37
After Hours:
26.58
0.02
+0.08%
Moderna Inc stock is traded at $26.56, with a volume of 30.65M.
It is down -1.37% in the last 24 hours and down -4.53% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.93
Open:
$26.345
24h Volume:
30.65M
Relative Volume:
2.87
Market Cap:
$10.27B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.0424
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+1.14%
1M Performance:
-4.53%
6M Performance:
-38.32%
1Y Performance:
-82.47%
1-Day Range:
$25.60
$26.81
1-Week Range:
$25.60
$27.85
52-Week Range:
$23.15
$158.82
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.56 | 10.16B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Health and Human Service cancels funding to Moderna - The San Joaquin Valley Sun
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - Reuters
Moderna Bird Flu Vaccine Funding Canceled - Effingham Radio
Two Sigma Advisers LP Sells 252,800 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
US cancels $590 million contract with Moderna for bird flu shot - Watauga Democrat
HHS pulls funding on bird flu vaccine for humans - MEAT+POULTRY
HHS Cancels $590M Avian Flu Vax - Contract Pharma
Lansforsakringar Fondforvaltning AB publ Invests $4.49 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS cancels Moderna’s $590 million contract for bird flu vaccine - Ponca City News
Trump administration cancels $766 million Moderna contract to fight pandemic flu - The Lawton Constitution
Moderna, Inc. (NASDAQ:MRNA) Holdings Reduced by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Lazard Asset Management LLC Sells 11,516 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Trump administration pulls bird flu, other vaccine funding awarded to Moderna - CBS News
HHS cancels Moderna bird flu vaccine contract - The Iola Register
U.S. Cancels Contract With Moderna to Develop Bird Flu Vaccine - The New York Times
HHS cancels $766m bird flu vaccine contract with Moderna - Pharmaceutical Technology
Moderna at Bernstein Conference: Strategic Diversification Plans - Investing.com
Is Moderna Stock A Sell After RFK Jr. Yanks Its Bird Flu Vaccine Funding? - Investor's Business Daily
HHS terminates Moderna contract to develop bird flu vaccine - BioPharma Dive
US cancels more than $700 million funding for Moderna bird flu vaccine - Reuters
HHS terminates Moderna’s funding for bird flu vaccine, calls mRNA 'under-tested' - The Business Journals
Transcript : Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10 - marketscreener.com
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot - Yahoo Finance
Moderna Is Imperiled by Kennedy’s Health Department. It May Run Out of Cash. - Barron's
Trump administration cancels $766 million Moderna contract to fight future pandemics, including bird flu - NBC News
U.S. Ends $600M Moderna Bird Flu Vaccine Contract - HomeTown Register
HHS cancels $590 million contract with Moderna for bird flu vaccine - WYFF
HHS, led by vaccine skeptic RFK Jr., cancels contract to fight flu viruses - LiveNOW from FOX
Moderna: positive results for H5 avian influenza vaccine - marketscreener.com
Moderna (MRNA) Faces Uncertainty After $766M Contract Termination - GuruFocus
Trump administration cancels $766 million contract with Moderna to develop vaccine against pandemic flu viruses - Fortune
U.S. cancels Moderna bird flu vaccine contract amid mRNA reevaluation - Farm Progress
Moderna Loses $760M+ Government Bird Flu Contract as Vaccine Uncertainties Mount - BioSpace
Big blow to Moderna vaccine projects as Trump cancels over $700 million funding - The Economic Times
Trump administration yanks Moderna's bird flu vaccine research funding even as company reports promising test results - CBS News
Moderna stock steady as HHS ends vaccine contract (MRNA:NASDAQ) - Seeking Alpha
Trump Team Pulls $766M Funding Plug on Moderna’s Bird Flu Vaccine - TipRanks
Moderna’s H5 avian flu vaccine shows promise in early trial By Investing.com - Investing.com South Africa
US cancels $766 million pandemic flu vaccine support to Moderna - India Today
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort - Benzinga
Trump admin cancels $766m Moderna contract to fight pandemic flu - MSN
US cancels $700m in funding for Moderna's bird flu vaccine - The Express Tribune
Moderna Says Investigational Influenza Vaccine Boosts Immunity; US Government to Terminate Funding - marketscreener.com
Blue Sky Capital Consultants Group Inc. Purchases Shares of 14,563 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Woodline Partners LP Purchases 10,968 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
U.S. Government cancels $766 million Moderna contract to fight pandemic flu - The Hindu
Moderna, Inc. (MRNA) Reports Strong H5 Avian Flu Vaccine Data Despite HHS Funding Cut - Yahoo Finance
Moderna Stock Drops On HHS Funding Termination For Pandemic Flu Vaccine; Retail Turns Bearish By Stocktwits - Investing.com India
Trump administration cancels $766 million contract to develop mRNA-based flu vaccines - FOX 13 News Utah
Trump administration cuts $766 million in funding to Moderna for bird flu, pandemic vaccine projects - Times of India
Trump's HHS cancels Moderna's $590M bird flu vaccine award - Axios
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):